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Abstract  
Chemotherapy induced peripheral neuropathy (CIPN) is a major challenge, with increasing impact as 
oncological treatments, using potentially neurotoxic chemotherapy, improve cancer cure and survival. 
Acute CIPN occurs during chemotherapy, sometimes requiring dose reduction or cessation, impacting on 
survival. Around 30% of patients will still have CIPN a year, or more, after finishing chemotherapy.  
Accurate assessment is essential to improve knowledge around prevalence and incidence of CIPN. 
Consensus is needed to standardize assessment and diagnosis, with use of well validated tools, such as 
the EORTC-CIPN 20. Detailed phenotyping of the clinical syndrome moves towards a precision medicine 
approach, to individualize treatment. Understanding significant risk factors and pre-existing vulnerability 
may be used to improve strategies for CIPN prevention, or to use targeted treatment for established 
CIPN.  
No preventive therapies have shown significant clinical efficacy, although there are promising novel 
agents such as histone deacetylase 6 (HDAC6) inhibitors, currently in early phase clinical trials for cancer 
treatment. Drug repurposing, e.g. metformin, may offer an alternative therapeutic avenue.  Established 
treatment for painful CIPN is limited. Following recommendations for general neuropathic pain is logical, 
but evidence for agents such as gabapentinoids and amitriptyline is weak. The only agent currently 
recommended by the American Society of Clinical Oncology is duloxetine.  
Mechanisms are complex with changes in ion channels (sodium, potassium and calcium), Transient 
Receptor Potential (TRP) channels, mitochondrial dysfunction, and immune cell interactions.  Improved 
understanding is essential to advance CIPN management. On a positive note, there are many potential 
sites for modulation, with novel analgesic approaches.  
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Introduction 
Chemotherapy induced peripheral neuropathy (CIPN) is a common and challenging complication arising 
from treatment with many commonly used anti-cancer agents.  A number of factors have contributed to 
the increasing prevalence of CIPN, including an increased incidence of cancer, with improved survival 
and cancer cure rates.  CIPN can occur acutely, during chemotherapy. If severe, it can require a 
reduction in the dose of chemotherapy, or even stopping prior to completing the planned course[34; 
45]. Clearly, this may have implications for efficacy of oncological treatment and survival. Whilst in many 
cases, acute CIPN will resolve after finishing chemotherapy, in a number of cases, it will persist, resulting 
in chronic symptoms, months, or even years later.  In some cases, CIPN can emerge shortly after 
finishing chemotherapy, a phenomenon known as “coasting” [34]. For neurotoxic chemotherapy overall, 
the prevalence of CIPN 1 month after finishing chemotherapy is around 68%, with this dropping to 60% 
at 3 months and 30% at 6 months or more [88]. The type of chemotherapy does influence the risk of 
developing CIPN, although even with single chemotherapeutic agents there is often a wide range of 
reported occurrence (see table1). Some potential confounders that may affect the reported incidence or 
prevalence include how CIPN was defined and assessed; differing dosing regimens, assessment time 
point(s), and exclusion of participants with pre-existing neuropathy.  
The clinical syndrome. 
CIPN develops as a glove and stocking neuropathy, although in more severe cases it can spread 
proximally affecting most of the limbs. Whilst it is predominantly a sensory neuropathy, autonomic 
function can also be affected, as can fine motor function and proprioception, with evidence for loss of 
sensory fibres and reduced intraepidermal nerve fibre density (IENFD)[8; 13; 15] [106]. Sensory 
dysfunction is wide ranging, with both positive and negative sensory signs, some of which are more 
often associated with particular types of chemotherapy e.g, cold hypersensitivity during platinum-based 
therapy. Neuropathic descriptors such as burning, and shooting are often used, along with numbness 
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and paraesthesia, although pain is not always a presenting feature[42]. CIPN can persist for many years, 
with a detailed assessment of long term survivors of childhood cancers finding ~48% of individuals 
having some evidence of neuropathy: predominantly sensory dysfunction and reduced quality of life[51] 
Some of the clinical features of CIPN are shown in figure 1.  
Assessment and diagnosis 
Accurate assessment and diagnosis are not only the first steps in successful management, but are also 
important in understanding the epidemiology of CIPN.  For painful CIPN, using a standard approach to 
neuropathic pain, the NeuPSIG guidelines for assessment and diagnosis of neuropathic pain can be 
applied. These guidelines recommend the use of screening questionnaires to identify potential patients, 
with a range of questionnaires available, many of which may not have been validated for CIPN [50]. 
Clinical examination is also an important part of assessment, but may have some challenges in non-
specialist settings, particularly where using more detailed sensory profiling for definitive diagnosis[105] 
[44]. 
It could be argued, however, that painful CIPN is a particular case, with circumstances that require a 
more tailored approach than that used for general neuropathic pain:  
• There is predictable delivery of a known toxic, but necessary, insult (chemotherapy) given 
repeatedly over the course of a number of weeks to months.  
• Completing the chemotherapy dosing regimen maximizes the chances of cancer survival,  with 
any dosage modification impacting on this; 
• Development of CIPN during treatment may necessitate dose reduction or cessation, with early 
identification of symptoms important in planning care; 
• CIPN mechanisms may be specific to the chemotherapy given. 
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The approach to CIPN may therefore require a more “bespoke” assessment process that is designed to 
identify the particular characteristics of CIPN, as early as possible, to allow appropriate management 
(including potential alteration to the chemotherapy regimen). This has been recognised with the 
development of a number of screening tools specific for CIPN (see below).  
Some have been developed for specific chemotherapeutic agents, such as the Functional Assessment of 
Cancer Therapy (FACT)–Taxane. This has been extensively validated, and is sensitive to change[38].  The 
EORTC-CIPN 20 can be used for any type of neurotoxic chemotherapy and has been rigorously studied.  
Some of the questions in the CIPN20 may potentially be less reliable – particularly those in the 
autonomic subscale, with the potential for reducing the length of the questionnaire without impacting 
on its performance. Rasch analysis revealed some inconsistencies, with evidence of a floor effect, and 
some issues with item scaling[95-97]. A reduced version of the CIPN20 – the CIPN 15 may address some 
of these concerns, with the added benefit of a reduced questionnaire burden on patients [96]. The Total 
Neuropathy Score (TNSc(©)) performs reasonably well, with a mix of clinician-detected signs and patient 
self report, but it doesn’t specifically assess pain. Rasch analysis revealed some inconsistencies with the 
7 item tool, and has suggested a shortened 5 item version may perform better[11; 20]. 
One of the widely used clinical tools for detecting neuropathy during chemotherapy  is the National 
Cancer Institute – Common Terminology Criteria for Adverse Events (NCI-CTCAE), but it is was not 
specifically developed to assess pain, is not sensitive to change and has significant inter-rater 
variability[19]. While many studies have used this to identify CIPN, particularly older studies, it is not a 
reliable assessment tool for clinical research, although may still have some clinical utility[35].  
This lack of consistency in assessing CIPN has implications for accurate epidemiological studies, including 
those of risk factors[98]. This issue has been identified in several systematic reviews, where many 
different primary outcome measures (or combinations) were identified, with almost half of studies not 
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even clearly defining a primary outcome measure[39; 88]. The need for a more uniform approach to 
assessment and diagnosis, in future studies, has been highlighted, although debate remains about the 
ideal tool to use [18; 37]. In clinical practice, a simple tool that can be used by non-specialists, to detect 
abnormalities early is needed. For research purposes, there is a need for a tool that performs 
consistently in different settings, with good reliability, sensitivity to change, detects key early symptoms 
of development (see figure 2).  
Confirming a definitive diagnosis of CIPN does require more detailed phenotyping than a single 
assessment tool. Psychophysical testing is useful in the research setting, with the potential to use a 
modified approach for routine clinical use in the cancer setting [87; 107]. Nerve conduction studies are 
less sensitive at identifying CIPN than quantitative sensory testing (QST) with sensory fibres 
preferentially affected, although this may vary between chemotherapy type, and change as neuropathy 
develops. Decreases in IENFD correlated with altered QST, particularly for mechanical sensation, in 
patients with chronic CIPN after docetaxol or oxaliplatin [55]: After vincristine treatment, myelinated A-
beta fibres were affected first, followed by A-delta and c fibres[29]. In patients with bortezomib induced 
CIPN no changes were identified in intraepidermal nerve fibre density, but there were clear reductions 
in subepidermal nerve fibre density of PGP9.5, with associated axonal swelling, and reduced sensory 
action potentials in the sural nerve[8].  Other studies of persistent CIPN after bortezomib, found a clear 
reduction in IENFD and Meissner’s corpuscles, with associated abnormalities in QST[14]. These 
differences may be due to time point of testing, dosing regimen, or other factors, and emphasise the 
need for consistent approaches to assessment to give a detailed and accurate understanding of the 
natural history of CIPN.    
Risk factors and vulnerability 
Identifying who is at higher risk of developing CIPN would be an important step forwards. Large scale 
population based studies combined with careful phenotyping is a potential approach to this. Are certain 
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individuals more vulnerable to the toxic insult of chemotherapy than others… and if so, how can we 
identify them?  
A number of factors have been identified, associated with an increased risk of developing CIPN, although 
causal links are less clear (see table 2). Some of these are potentially modifiable, giving opportunities for 
using approaches to reduce CIPN development. Perhaps the most obvious ones are type and cumulative 
dose of chemotherapy, although here the challenge is to understand how alterations in dosing regimes 
might impact on cancer survival. Better understanding of this might allow a more individualised 
approach to chemotherapy dosing. For example, if individual is generally more sensitive to 
chemotherapy (i.e both toxic and therapeutic effects), it may be that reducing the dose does not impact 
on individual survival: this needs further study. 
It may be possible to use detailed phenotyping to identify pre-existing vulnerability to developing CIPN. 
This approach is showing promise in some other areas, such as persistent post-surgical pain, [52; 61; 62; 
100; 110]. QST has identified subclinical deficits in cancer patients prior to starting chemotherapy, 
compared to healthy controls, with those individuals showing the most marked deficits at higher risk of 
developing clinically significant CIPN. These findings were similar to a retrospective study of head and 
neck cancer patients, prior to starting chemotherapy, those with altered QST (and fine motor function) 
were at higher risk of developing CIPN [24; 83]. Predictors emerging during early chemotherapy have 
also been identified, with thermal hyperalgesia predicting development of severe oxaliplatin CIPN[5]. 
Our preliminary work, using functional neuroimaging,  has also found structural and functional changes 
in the brain in pain processing areas, detected prior to starting chemotherapy, potentially indicating a 
pre-existing vulnerability to developing CIPN [89]. 
A number of studies have explored genetic factors in determining risk of developing CIPN. Studies using 
multivariate statistical modelling have identified several risk factors, including smoking, decreased 
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creatinine clearance and baseline neuropathy, although there may be some statistical bias introduced by 
the techniques used [5; 28; 88]. Informed by other Genome Wide Association Studies (GWAS), a study in 
more than 1000 patients with multiple myeloma identified 13 Single Nucleotide Polymorphisms (SNPs) 
associated with CIPN development, of which 4 were relevant for neural function[65]. A GWAS in breast 
cancer patients found that severe taxane related CIPN was associated with genes involved in diabetes 
and diabetic neuropathy, with the G allele of  rs1858826 in GNGT1 decreasing CIPN risk[98]. A recent 
review of predictive biomarkers for CIPN found 3 genetic biomarkers that have been consistently 
identified in a number of studies: ARHGEF10 rs9657362 (neuronal morphogenesis), CYP2C8 
rs11572080/rs10509681 (drug metabolism) and FGD4 rs10771973 (mutations found in Charcot-Marie 
tooth disease)[26]. Some studies have also found associations with genes associated with mitochondrial 
dysfunction, which may link with preclinical evidence for underlying mechanisms of CIPN development 
(see section below)[54].  
CIPN Prevention 
To date there are no preventive treatments for CIPN.  This lack of any effective neuroprotective agents is 
a key area of unmet clinical need. While a number of trials having studied agents that may potentially 
modify CIPN development by targeting the underlying mechanisms, there is as yet insufficient evidence 
to recommend any specific agent[46]. There have been quite a number of CPIN prevention trials, many 
with small sample size, none of which have yielded high quality evidence. Agents that have been studied 
in clinical trials, often based on postulated effects on underlying mechanisms, include: Acetyl-L-carnitine 
(ALC)(associated with worse outcomes),  amifostine, N-acetylcysteine, amitriptyline, nimodipine, 
glutathione, carbamazepine, Vitamin E,  omega-3 fatty acids, or oxycarbazepine [2; 4; 46-48; 111]. 
Prevention trials face a number of design challenges, including whether to treat all patients receiving 
neurotoxic chemotherapy, accepting that some of them would not develop CIPN anyway.  Not only does 
this increase the required sample size, but also exposes patients to a novel therapy unnecessarily. This is 
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one area where identification for pre-existing vulnerability could improve clinical trial design. An 
alternative approach to prevention trials is to look at intervening when there are early (or subclinical 
signs of CIPN), using a detailed phenotyping approach [30; 37; 39; 63]. 
Treatment strategies 
There is a lack of good quality clinical trials focusing on treatment of established painful CIPN, with a 
pragmatic approach extrapolating from evidence and guidelines for treatment of other types of 
neuropathic pain. Duloxetine is one of the few agents where there is a positive RCT in CIPN[94]. This is 
reflected in Clinical Practice Guidelines from ASCO, where duloxetine is the only treatment where there 
is sufficient evidence to recommend its use. However, based on efficacy in other neuropathic pain 
syndromes, other agents can be trialled, including tri-cyclic anti-depressants, gabapentin and topical gel 
(baclofen (10 mg), amitriptyline HCL (40 mg), and ketamine (20 mg),) that had limited positive evidence 
from one trial[46]. 
Non-pharmacological treatments may also be useful, although again with a mixed evidence base. A 
recent review of pharmacological strategies identified a number of current clinical trials of non-drug 
strategies, including exercise, acupuncture, massage, and nutritional interventions, not all of which were 
based on strong underlying hypotheses[21] An RCT of a 6 week exercise programme showed small to 
moderate improvements in CIPN symptoms[53]. With the known benefits of exercise in chronic pain and 
cancer, combined with low risk of harm, supporting an increase in physical activity should be part of 
CIPN management[60; 108]. 
 
Mechanisms 
By improving our understanding of the underlying mechanisms leading to the development and also 
factors contributing to chronicity, we can develop targeted treatments to reduce the significant impact 
that CIPN has on patients. The mechanism are complex, with peripheral, spinal and supraspinal changes, 
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ranging from altered ion channel activity to changes in intracellular systems.  A comprehensive analysis 
of these  is beyond the scope of this review, and readers are referred to several  recent reviews[15] [63]. 
It is, however, worth considering some of these mechanisms and how they might translate into clinical 
benefit. An overview is given in figure 3.  
Ion channels 
Sodium channels: In CIPN, as in some other types of neuropathic pain, alterations in sodium channel 
type and activity may contribute to the development of CIPN[27]. Expression of Nav1.7 channel is 
increased in small fibre sensory neurones, in preclinical CIPN models, with increased spontaneous 
neuronal activity, with similar findings in human dorsal root ganglia in segments affected by CIPN [58]. 
An acute, Na channel mediated in neuronal excitability has been found in oxaliplatin treated patients 
who go on to develop chronic CIPN[77].  
Potassium channels: Decreased potassium channel expression in primary sensory neurones has been 
found with several chemotherapy types, potentially leading to increased spontaneous neuronal 
firing[81; 112]. 
The combination of increased between Na channel and decreased K channel activity also predisposes 
towards hyper excitability, with agents that increase K channel hyperpolarization reducing CIPN 
features.[25; 72]. 
Calcium channels: Alterations in ion channel function and expressed subtypes have been widely 
described in neuropathic pain syndromes, including CIPN.  Increase coupling of pre-synaptic calcium 
subunits (alpha-2 delta1) with the NMDA receptor has been shown in mice after paclitaxel, contributing 
to neuropathic pain features[22] . Type of chemotherapy may be important, with a decrease in Cav3.2 T 
type calcium channel was found with bortezomib, in mouse dorsal root ganglia[101]. However, in a rat 
model of paclitaxel neuropathy increased expression of Cav3.2 was found, associated with increase 
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spontaneous activity in dorsal root ganglia neurones. Interestingly, this increased activity was found 
with infusion of lipopolysaccharide (an agonist at TLR4 receptors), and blocked by administration of a 
Cav3.2 inhibitor[59].   
Transient Receptor Potential (TRP) channels:  The TRP channels are known to be important in pain 
processing and thermal sensation, with demonstrated changes in neuropathic pain. Of these channels, 
the TRPVanilloid 1 (TRPV1) is activated by noxious heat, low pH, and by exogenous capsaicin [84; 90]. It 
is found on c fibres and is upregulated in neuropathic pain conditions. Several rodent models of CIPN 
(rat and mouse) have shown increases in TRPV1 expression and activity, with evidence of thermal 
hyperalgesia[41; 80; 99]. Clinically, a high dose 8% capsaicin patch has been used topically for focal 
neuropathic pain: while there is limited high quality evidence for its use specifically in CIPN, there have 
been some reports of efficacy[16; 32]. The TRPM8 channel, activated by non-noxious cool temperatures, 
is upregulated on a subset of c fibres in neuropathic pain. Activation of the TRPM8 receptors by topical 
agents, such as icilin and menthol (in percentages less than 10%), results in analgesia in rodent models 
of neuropathic pain, with some early clinical evidence of efficacy for menthol in CIPN[31; 79]. 
Endocannabinoid systems 
There are a number of models showing involvement of endocannabinoids in CIPN, with potential for 
analgesia through agents with activity at CB1 and/or CB2 receptors, which may be peripheral or 
central[71; 109]. Inhibition of endocannabinoid metabolism is an alternative approach, via inhibition of 
fatty acid amide hydrolase (FAAH) [10; 74]. There have been a number of early phase clinical trials 
investigating this class of drugs. Unfortunately, in a phase 1 study of a FAAH inhibitor (BIA 10-2474), 
there were serious adverse events, resulting in the death of one participant, and 5 other hospitalised 
with neurological issues[67]. This led to all clinical trials using FAAH inhibitors being stopped at that 
point. Subsequent evidence indicates that the SAEs were related to wider “off target” effects of BIA 10-
2474, rather than a class effect of FAAH inhibitors, with clinical trials now resuming in this area[104] 
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Mitochondrial dysfunction 
Mitochondria are small membrane bound intracellular organelles that provide cellular energy mainly via 
oxidative phosphorylation to produce adenosine triphosphate (ATP). Neuronal cells have high energy 
requirements, and as such, are sensitive to process that disrupt mitochondrial function, such as 
chemotherapeutic agents[76]. Different agents appear to have different mechanism by which 
mitochondrial dysfunction occurs. For example, platinum based compounds may affect protein synthesis 
within mitochondria, whereas taxanes impact on membrane depolarization with changes in calcium 
release[63].  As a result, there is an increase in oxidative stress within mitochondria and consequent 
continued dysfunction in neuronal energy production. Reduced maximal respiration capacity and 
mitochondrial basal respiration as well as reduced ATP production are all seen, with an increase in 
Reactive Oxygen Species (ROS) overwhelming endogenous anti-oxidant systems [9; 33; 34; 113]. 
Understanding these mechanisms and targeting them is one potential preventive strategy[63].   
Non neuronal mechanisms 
Inflammatory processes induced in central glial cell, and peripheral immune cells, contribute to CIPN 
development[63; 70]. A number of mechanisms are involved in these processes. Paclitaxel-induced 
microglial activation, with an increase in calcium/ calmodulin- dependent protein kinase II (CAMKII) 
stimulated overexpression of Brain Derived Neurotrophic Factor (BDNF), produced high levels of the 
pro-inflammatory cytokine,IL-6, and increased expression of NR2B glutamate receptor subunits. All 
these changes were reduced by administration of a CB2 receptor agonist [109]. Another study found 
that paclitaxel induced significant upregulation in IL-1α, IL-1β, IL-6, TNF-α, INF-γ and MCP-1, which was 
attenuated by a TNF-alpha monoclonal antibody (etanercept) [1] In a vincristine CIPN model, the anti-
inflammatory cytokine, IL-4, and associated STAT signalling was reduced, with an increase in pro-
inflammatory cytokines such as IL-1-beta and TNF-alpha[92].  IL-10, an anti-inflammatory cytokine, may 
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be important in recovery from CIPN, with preclinical evidence from both platinum and taxane-related 
CIPN [63]. 
Peripheral immune system cells such as macrophages and monocytes have been shown to be part of 
CIPN mechanisms. There may therefore be the potential for developing novel therapies with a unique 
mode of action, such as the chemokine CX3CL1 (fractalkine) and its receptor, expressed on monocytes, 
and important in communication with neuronal cells[70]. 
Matrix metalloproteinases (MMPs) are a class of enzymes involved in degradation of the extracellular 
matrix, with inhibitors showing some potential as anti-cancer agents [49]. An increase in MMP 2 and 9, 
with a decrease in the endogenous MMP inhibitor, TIMP1, was found in a paclitaxel mouse model, 
associated with the development of allodynia. If inhibited by intrathecal MMP9 monoclonal antibody, 
allodynia was reduced. In parallel, reductions in oxidative stress and inflammatory mediators were 
found in the dorsal root ganglia[102]. 
Central changes 
There have been a few studies using neuroimaging in CIPN. There are clear changes in pain processing in 
response to a noxious stimulus compared to healthy volunteers, and to patients with cancer, but no 
CIPN. These altered responses are seen in areas of the brain involved in pain processing, such as the 
superior frontal gyrus, cingulate cortex and insula. Structural changes have also been seen with altered 
grey matter density[12; 73].  
Discussion  
In developing novel preventive or modifying treatment for CIPN, the complex interaction between 
cancer cells, immune system and neurons must be considered. In particular any novel therapies used 
during oncological treatment, must not interfere with the tumoricidal effects of chemotherapy. This 
creates an additional challenge compared to other types of neuropathic pain.  
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While there are some potential novel therapies to be explored for prevention and treatment of CIPN, 
there remains an urgent need to improve the efficiency of translation[93]. This will require true 
collaboration between clinicians, basic scientists and population health scientists. Lessons need to be 
learned from previous failures to translate promising compounds in preclinical models, and sometimes 
early phase clinical trials to clinical benefit. We need to consider how design of preclinical studies can be 
improved. As with clinical evidence, critical appraisal of the quality of preclinical studies, and risk of bias 
need to be considered. Issues such as proper sample size calculations, blinding and prospectively 
defined primary outcome measures should all be considered[3]. The relevance of the model to the 
clinical syndrome is also important, e.g. including behavioural assessment of spontaneous pain, studying 
male and female rodents[7; 69]. 
Developing the use of neuroimaging and QST to better understand CIPN mechanisms in the clinical 
syndrome should also help increase successful translation, allowing direct study of pharmacodynamic 
effects, stratification of clinical trials by mechanisms, and identification of placebo responses. Whilst 
there are not yet clear clinical biomarkers that can be used to identify patients who are inherently more 
vulnerable to developing CIPN, or more likely to respond to a particular targeted treatment, using  this 
approach, with detailed phenotyping (including validated patient self report questionnaires, 
psychophysical testing, genetic testing and neuroimaging) is a definite step towards this. Although not 
practical for routine clinical use, it may then be possible to move towards simple bedside tests as 
surrogate markers, directing individual treatment, and improving clinical trials for CIPN. A recent 
consensus meeting (Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, 
Opportunities and Networks (ACTTION)–Consortiium) has produced very useful recommendations about 
future trial design for CIPN, addressing many of these issues[37]. One area that needs to be explored 
further is whether or not sensitivity to chemotherapy is reflected in the efficacy of cancer treatment. If 
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so, then it may be that more “personalised” chemotherapy regimens should be used, taking account of 
chemo sensitivity both in terms of efficacy and adverse effects, such as CIPN.  
Summary 
Using a strong translational approach to the problem of CIPN is most likely to be successful. Well-
designed preclinical studies, reflecting the clinical situation as much as possible, combined with careful 
consideration of clinical trial design is needed. Working together to standardize assessment techniques 
and ensure that those used are robustly validated is important. Underlying CIPN mechanisms are wide 
ranging and therefore offer multiple targets for novel therapies. Whilst traditionally, pharmacological 
interventions have predominated, a holistic approach, with consideration of mechanistically driven non-
pharmacological interventions is also needed. Collaboration will be the key to success, both between 
disciplines and countries – a challenge not to be underestimated, with many potential barriers and 
rewards.   
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Table1: Common chemotherapeutics and incidence or prevalence of reported neuropathy.    
Chemotherapy Approximate incidence/ prevalence of CIPN (%) 
Oxaliplatin  Acute: 85-96; Chronic wide range: 40-93 
Cisplatin 12-85 
Paclitaxel 61-92 
Bortezomib 47 
Vincristine 20 
Combined cisplatin and paclitaxel 69-76 
Supporting references: see [16; 24], [88] Data is mainly from randomised controlled trials or prospective 
cohort studies.  
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Table 2: Some of the risk factors associated with an increased risk of developing CIPN 
Risk factor Comments Reference 
Older age May not due to lower chance of recovery from acute CIPN [17; 78] 
Medication: 
cardiovascular 
especially  beta 
blockers 
Opportunity to modify medication prior to starting 
chemotherapy.  
[85] 
Co-morbid health 
conditions 
Those where there may be associated increased risk of 
neuropathy e.g. diabetes, HIV, excess alcohol, smoking; 
decreased creatinine clearance 
[28; 88] 
Raised Body Mass Index 
(BMI) 
Potential mechanism not well understood, but may be related 
to pro-inflammatory state associated with obesity 
 
Low serum albumin May reflect lower general health status [40] [54; 
82] 
Use of opioids Prolonged use more likely in patients with CIPN. Need further 
work to understand l if this is due to pain severity, or to a 
mechanistic interaction with opioids increasing CIPN risk (OR 
2.0, 1.06-3.69) 
[91] 
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Table 3: Some selected mechanisms by which chemotherapy may cause development and persistence of 
painful peripheral neuropathy 
Potential mechanism of 
chemotherapy mitochondrial 
damage 
Agent; action References 
Increased mitochondrial p53 
(tumour suppressor molecule): 
Reduces mitochondrial membrane 
potential 
Pifthrin-mu: prevents p53 accumulation in 
mitochondria without interfering with 
cancer killing effects of chemotherapy 
[66] [57] 
Disrupted axonal mitochondrial 
capacity via Histone diacetyl-6 
(HDAC6) (deacetylates a range of 
substrates in the cytosol, such as 
tubulin and heat shock protein 90) 
HDAC6 inhibitors: reverses/ prevents CIPN in 
preclinical models. Early stage clinical trials 
underway  of safety in a variety of cancers, 
none focussing on CIPN (e.g.NCT02935790, 
NCT02632071, NCT02635061) 
[56] [23; 86] 
 
Reduced energy metabolism Metformin: enhanced activation of carnitine 
palmitoyltransferase I, restoration of 
membrane potential; no clinical trials 
registered currently 
[114] [43; 64; 
75] 
Increase in reactive oxygen species, 
overwhelming of endogenous 
mitochondrial  anti-oxidant 
systems 
Targeted mitochondrial anti-oxidants; 
accumulate in mitochondria and prevent 
CIPN related damage 
[6; 36; 68] 
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Reduced mitochondrial respiration 
and energy production 
Mitochondrial targeted peptide (SS 20): 
promotes mitochondrial respiration and 
positive effect on energy producing 
mechanisms 
[103] 
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Figure legends 
Figure 1: Clinical features of CIPN.  
Figure 2:  Important components of CIPN assessment tools. 
Figure 3: Overview of CIPN mechanisms and treatments. 
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